Why We Invested In Transcera — Ceramide Therapeutic Platform

1 min read

Excited to announce our investment in the seed for Transcera, a biotech company developing a ceramide lipid-based drug delivery platform that utilizes active transport pathways to increase drug absorption. We are joined by Xora Innovation, an early-stage deep tech investment platform of Temasek, Digitalis Ventures, Pear VC, and KdT Ventures. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in mature seed, typically when there is a pipeline of customers. We found Transcera to be exciting for several reasons: (1) big need (2) high-caliber team and (3) product opportunity. 1) The Need A key factor in dosing for biologic drugs used for prevalent…...

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

sharonshuang MD Candidate | VC in Healthcare, Digital Health
Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.